Key Market Indicators
France, Italy and China respectively ranked numbers 2, 3 and 4 in this ranking. Sales of diabetes medicines in Germany will reach nearly $4 billion by 2026, up 1.9% on average each year since 2021 and 6.1% since 1991. Canada, Spain and Italy are the second, third and fourth-largest markets, respectively. Exports of German insulin are set to reach $4.1 billion by 2026, growing at a rate of 0.9% per year since 2021 and decreasing 0.8% a year since 1996. France, Italy and China are the second, third and fourth-largest suppliers, respectively. Imports of German insulin are set to reach $763 million by 2026, growing at an average of 0.9% per year since 2021 and increasing 3.5% a year since 1996. France, Italy and China are the second, third and fourth-largest importers, respectively.
